Wegovy and Heart Health: What the SELECT Trial Shows
Our Team
11/21/2026
Headlines about Wegovy and the heart can blur three questions: Who was studied, how large was the benefit, and what does an approval mean for an individual? For Los Angeles adults considering the evidence, separating those questions makes a conversation with a clinician more useful.
What did the FDA approve?
The FDA’s March 2024 approval expanded Wegovy (semaglutide) injection’s use to reduce the risk of a combined outcome of cardiovascular death, nonfatal heart attack or nonfatal stroke in adults with established cardiovascular disease and either obesity or overweight. It is used alongside a reduced-calorie diet and increased physical activity.
Established disease matters. This indication is not a blanket heart-protection recommendation for everyone who wants to lose weight. Ask which documented condition supports the proposed treatment goal.
Who participated in SELECT?
The original SELECT design paper specified adults aged 45 or older with a body mass index of at least 27 and established cardiovascular disease, including a previous heart attack, previous stroke or symptomatic peripheral artery disease. People with a history of diabetes were excluded.
These details define the research population, rather than a checklist for diagnosing yourself. A family history of heart disease or an elevated cholesterol result alone does not reproduce the trial’s eligibility. SELECT does not directly answer every question about preventing a first cardiovascular event.
Read the benefit in absolute and relative terms
The original SELECT results included 17,604 participants randomly assigned to injected semaglutide or placebo. Over an average follow-up of 39.8 months, the combined outcome of cardiovascular death, nonfatal heart attack or nonfatal stroke occurred in 6.5% of the semaglutide group and 8.0% of the placebo group.
That is an absolute difference of 1.5 percentage points: approximately 15 fewer participants with an event per 1,000 treated over the study’s follow-up. The reported hazard ratio of 0.80 describes a 20% relative reduction in the hazard of that combined outcome. These are different ways to describe the result, not interchangeable percentages.
Events occurred despite treatment; individual benefit is uncertain. Novo Nordisk funded SELECT.
Keep established heart care in place
Participants in both groups received standard medical care, including blood-pressure and cholesterol management, plus healthy-lifestyle counseling. The research tested an addition to that care. It did not test replacing existing heart medicines with Wegovy.
NIH guidance for coronary heart disease describes a plan that may involve lifestyle changes, medicines and procedures, depending on the person. Discuss blood pressure, cholesterol, smoking, activity and nutrition with your usual care team. Ask what level of exercise is appropriate before starting a new program.
Bring your current medicine list to the discussion. If several clinicians are involved, clarify who will review the complete plan and communicate changes. Continue prescribed heart care unless your treating clinician recommends a change.
Check the exact product and intended use
The prescribing information available today lists the cardiovascular indication under both Wegovy injection and Wegovy tablets. SELECT studied injected semaglutide. Ask which approved formulation and treatment plan apply to the discussion; do not switch products on your own.
FDA distinguishes off-label use from an approved indication. When an approved medicine is proposed for an unapproved use, FDA has not established its safety and effectiveness for that use. Ask the clinician to explain the evidence for the particular goal being discussed.
A compounded product is a separate issue: compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness or quality before marketing. A product advertised as compounded semaglutide should not be assumed to carry Wegovy’s approval or SELECT’s demonstrated outcomes.
Give the risks their own discussion
Wegovy is contraindicated with a personal or family history of medullary thyroid carcinoma, MEN 2, or hypersensitivity to its ingredients. Its boxed warning describes thyroid C-cell tumors in rodents; the human relevance is unknown. Other concerns include pancreatitis, gallbladder disease, severe gastrointestinal reactions and kidney injury from volume depletion. Nausea, diarrhea and vomiting are common adverse reactions.
Ask which concerns matter in your own history and how to report persistent or troublesome symptoms. Benefit and tolerability both belong in the decision.
Include the newest eye-safety update
On November 9, 2026, FDA required new GLP-1 safety labeling about a potential increased risk of non-arteritic anterior ischemic optic neuropathy, or NAION. This rare condition can cause sudden, painless vision loss, sometimes permanent.
Contact a healthcare professional right away for sudden vision loss, blind spots or other new visual disturbances. Report a previous NAION event during treatment planning. A clinician should help decide whether treatment should continue if an event occurs.
Prepare questions that connect the evidence to you
Bring existing cardiovascular records, your medicine and supplement list, and the questions you want answered. Ask: What is my treatment goal? How closely does my history resemble the studied population? What would follow-up involve? Who should receive updates?
Our peptide therapy benefits and risks guide can help frame broader questions about evidence and approval. Keep the exact medicine and intended use at the center of the discussion.
Frequently asked questions
Do I need diabetes to discuss this indication?
No. The cardiovascular indication requires established cardiovascular disease and obesity or overweight; it does not require diabetes. Individual suitability still needs evaluation.
Was SELECT a trial of preventing a first heart event?
No. Participants already had qualifying cardiovascular disease. Its results should not be automatically extended to people without established disease.
Does a 20% reduction mean my risk drops by 20 points?
No. That is a relative measure. The observed absolute difference was 1.5 percentage points over the trial’s follow-up.
Does compounded semaglutide have the same approval?
No. Compounded drugs are not FDA-approved. Discuss the exact product and the evidence supporting its proposed use rather than relying on a shared ingredient name.
Discuss your questions through California telehealth
Our peptide therapy information provides general context for a consultation. SoCal Testosterone Clinic offers California-only telehealth and does not provide in-person clinic appointments. You can contact SoCal Testosterone Clinic to discuss consultation options. Bring existing records and ask how your questions can be coordinated with your cardiovascular care team.
Recent Posts
TRT After Testicular Cancer: Questions for Survivors
Explore testosterone testing after testicular cancer, what survivor trials found, and questions to discuss with your cancer care team.
Wegovy and Heart Health: What the SELECT Trial Shows
Understand Wegovy’s cardiovascular indication, SELECT’s absolute and relative benefits, and why ongoing heart care still matters.
Zepbound and Sleep Apnea: What FDA Approval Covers
Learn who Zepbound’s sleep-apnea indication covers, what SURMOUNT-OSA studied, and how to coordinate medicine and PAP follow-up.